What is RLMD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.38B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RLMD?

P/E (TTM) is n/a and 52-week range is $2.15 to $8.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RLMD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RLMD?

The company profile lists net income (TTM) near -$103M, EPS (TTM) near -$0.96 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Relmada Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Coral Gables, Florida, US, 106.7M shares outstanding, ISIN US75955J4022 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Relmada Therapeutics Inc

$RLMD

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 17 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

Employees

Website

www.relmada.com/

IPO

2014-03-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US75955J4022

Headquarters

Coral Gables, Florida, US

Shares outstanding

106.7M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

91.17%

Browse other companiesFree AI scores and summaries for more stocks